New pill aims to tame phosphorus in kidney dialysis patients
NCT ID NCT07548853
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a new drug called TS-172 in 30 adults on peritoneal dialysis who have high phosphorus levels. Participants take the drug daily for several weeks to see if it can safely bring their phosphorus down to a target range. The goal is to find a better way to manage this common complication of kidney disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- TS-172 (a drug taken by mouth to lower phosphorus levels)
- What this could lead to
- If it works, this could offer a new treatment option to help control phosphorus levels in people on peritoneal dialysis.
- What could go wrong
- This is a small, early-phase trial with only 30 participants and no placebo group, so results may not apply broadly. The drug may not work or could cause side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC KIDNEY DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Taisho Selected Site
RECRUITINGTokyo, Japan
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Aging kidneys under the microscope: could a simple test predict failure?
- Could your gut bacteria hold the key to protecting your kidneys?
- Food as medicine: could cooking classes slow kidney disease?
- Could a phone app be the key to managing kidney disease?
- A new pill aims to slow kidney failure and save lives
- AI takes on kidney disease: a new model to forecast Who's at risk